AIRLINK 74.00 Decreased By ▼ -0.56 (-0.75%)
BOP 5.02 Decreased By ▼ -0.04 (-0.79%)
CNERGY 4.42 Decreased By ▼ -0.04 (-0.9%)
DFML 39.20 Decreased By ▼ -0.53 (-1.33%)
DGKC 86.09 Decreased By ▼ -1.46 (-1.67%)
FCCL 21.65 Decreased By ▼ -0.28 (-1.28%)
FFBL 34.01 Decreased By ▼ -0.58 (-1.68%)
FFL 9.92 Increased By ▲ 0.17 (1.74%)
GGL 10.56 Increased By ▲ 0.07 (0.67%)
HBL 113.89 Increased By ▲ 0.10 (0.09%)
HUBC 135.84 Decreased By ▼ -0.68 (-0.5%)
HUMNL 11.90 Increased By ▲ 1.00 (9.17%)
KEL 4.84 Increased By ▲ 0.17 (3.64%)
KOSM 4.53 Decreased By ▼ -0.11 (-2.37%)
MLCF 38.27 Decreased By ▼ -0.19 (-0.49%)
OGDC 134.85 Decreased By ▼ -1.29 (-0.95%)
PAEL 26.35 Decreased By ▼ -0.26 (-0.98%)
PIAA 20.80 Decreased By ▼ -1.69 (-7.51%)
PIBTL 6.68 Increased By ▲ 0.01 (0.15%)
PPL 123.00 Increased By ▲ 0.71 (0.58%)
PRL 26.69 Decreased By ▼ -0.28 (-1.04%)
PTC 14.33 Increased By ▲ 0.42 (3.02%)
SEARL 59.12 Decreased By ▼ -0.75 (-1.25%)
SNGP 69.50 Decreased By ▼ -0.56 (-0.8%)
SSGC 10.33 Decreased By ▼ -0.02 (-0.19%)
TELE 8.50 Decreased By ▼ -0.04 (-0.47%)
TPLP 11.23 Decreased By ▼ -0.11 (-0.97%)
TRG 64.85 Decreased By ▼ -1.15 (-1.74%)
UNITY 26.25 Decreased By ▼ -0.08 (-0.3%)
WTL 1.34 Decreased By ▼ -0.01 (-0.74%)
BR100 7,851 Increased By 26.3 (0.34%)
BR30 25,337 Decreased By -69.2 (-0.27%)
KSE100 75,207 Increased By 122.8 (0.16%)
KSE30 24,143 Increased By 49.1 (0.2%)
Technology

Startup aims to use gene-editing technology to treat heart diseases

In order to help treat lethal heart diseases, a new startup has proposed a plan to use the latest gene-editing tech
Published May 8, 2019

In order to help treat lethal heart diseases, a new startup has proposed a plan to use the latest gene-editing technology for achieving the goal.

Genetics already play a great role in figuring out people’s risk of developing heart disease or having a heart attack. A new biotech startup Verve Therapeutics has come up with an innovative plan to use CRISPR gene-editing technology to put an end to heart diseases.

CRISPR gene-editing includes a process by which genes are cut out of or inserted into a person’s DNA strand. As per Futurism, the firm’s plan is to use CRISPR in order to edit genes of adults with a greater genetic risk of heart problems so that they more closely resemble the genes of people with a naturally low risk of such ailments.

Researchers use gene-editing technology to treat fatal lung disease before birth

“Poor adherence, costs, side effects, limited access… all these challenges have limited the impact existing heart medications like cholesterol-lowering statins have had,” Sekar Kathiresan, Verve’s CEO, told Reuters.

The firm is currently exploring seven various genes that scientists have found leave people with a natural resistance to coronary artery disease. It plans to select one or two genes over the next year in order to initiate clinical trials. Verve believes that interesting one gene into a person’s DNA will permanently lower their bad cholesterol and cut down their livelihood of having a heart attack, as per Boston Business Journal.

“With our therapy, we could change the treatment paradigm for heart disease from chronic care, daily pills, or monthly injections to a one-and-done approach,” Kathiresan asserted.

Moreover, the Verve Therapeutics soon enough found a major firm to back it up. As per the firm, it had raised $58.5 million in financing, most of which came through GV (Google Ventures), the venture capital arm of Google’s parent company Alphabet.

“[Verve] has broad potential to address the number one leading cause of death in the world unlike anything we’ve seen before,” GV general partner Krishna Yeshwant said.

Copyright Business Recorder, 2019

Comments

Comments are closed.